N-Benzyl-2-Phenoxybenzamide EP2/EP4 Modulators for Targeted PGE2 Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective modulators for the EP2 and EP4 receptors of prostaglandin E2 (PGE2), which are implicated in various pathological conditions including cancer, pain, inflammation, neurodegenerative diseases, and kidney diseases, with existing treatments often being inadequate or non-specific.
Innovation Solution
Development of novel N-benzyl-2-phenoxybenzamide derivatives that act as potent modulators of the EP2 and/or EP4 receptors, providing targeted therapeutic options for conditions mediated by these receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used for treating conditions mediated by EP2 and EP4 receptors, then treatment coverage is provided, but the therapies lack effectiveness and specificity
Solution Approach 1:
The patent applies parameter changes by systematically varying molecular parameters of the compound structure (substituents at different positions on the benzamide core, variations in the A ring system, and modifications to the R groups) to optimize binding affinity and selectivity for EP2 and EP4 receptors. This approach transforms the general scaffold into specific high-efficacy modulators with tailored receptor interactions.
2Measurement precision
If non-specific treatments are used, then broad condition coverage is achieved, but treatment precision is inadequate
Solution Approach 1:
The patent implements local quality by introducing specific substituent groups at defined positions on the molecular scaffold. Each substituent (such as fluorine atoms, methyl groups, or heterocyclic rings at specific R positions) creates localized interaction zones that enhance binding to specific amino acid residues in the receptor binding pocket, thereby achieving precise receptor targeting while maintaining broad therapeutic applicability.
Data Source
AI summary
The present invention relates to novel, optionally substituted, N-benzyl-2- phenoxybenzamide derivatives of formula (I), as modulators of EP4 and/or EP2 receptors of prostaglandin E2 (PGE2), to processes for their preparation, to pharmaceutical compositions comprising said compounds and to said compound for use in the treatment of pathological conditions, disorders or diseases that can improve by modulation of EP4 and/or EP2 receptors of prostaglandin E2 (PGE2) such as cancer disease, pain, inflammation, neurodegenerative diseases and kidney diseases.